News
Update on 2025 NETRF Grant Cycle
At NETRF, our annual Request for Applications (RFA) is a cornerstone of our mission to fund innovative research in neuroendocrine cancer. This two-stage process is
Beyond Size: Rethinking How We Manage Small Pancreatic Neuroendocrine Tumors
By Anna Greene, PhD, Director of Research, NETRF Pancreatic neuroendocrine tumors (PanNETs) are a rare but increasingly detected cancer, thanks in part to more widespread
New Study Sheds Light on the Hidden Genetics of Metastatic Neuroendocrine Cancer
By Anna Greene, PhD, NETRF Director of Research Unlocking the Molecular Mysteries of Neuroendocrine Neoplasms (NENs) A study published this month by NETRF-funded Collaborative Grant
Clinical Trials Aim to Advance the Future of Neuroendocrine Cancer Care
Neuroendocrine cancer research continues to evolve, with a growing number of clinical trials exploring bold, highly targeted strategies aimed at treating advanced and high-grade disease.
CAR T-Cell Therapy for Neuroendocrine Cancer, Now in Clinical Trial, Receives FDA FAST TRACK Designation
(Boston, MA): The Neuroendocrine Tumor Research Foundation (NETRF) is proud to join Chimeric Therapeutics in announcing that CAR T-cell therapy using CHM CDH17 has been
New ALT Biomarker Enhances Prognostic Accuracy in Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors (PanNETs) can have a variety of behaviors. Some stay slow-growing for years, while others take a sudden, aggressive turn, even when they’re
Belzutifan Approved for Pheo Para
In a breakthrough for those with advanced pheochromocytoma and paraganglioma (Pheo/Para), the U.S. Food and Drug Administration (FDA) has approved WELIREG® (belzutifan) as a treatment
Driving Progress in NET Research: An Interview with Dr. Anna Greene
In a recent interview with CancerNetwork®, Dr. Anna Greene, Director of Research at the Neuroendocrine Tumor Research Foundation (NETRF), spotlighted the foundation’s leadership as the
CAR T-cell Clinical Trial Expands to Fourth Site
Patient enrollment has begun at a fourth site for the world’s first CAR T-cell therapy clinical trial for neuroendocrine cancer. Winship Cancer Center at Emory
Unlocking Personalized Treatment for Lung Neuroendocrine Tumors
Lung neuroendocrine tumors (lung NETs) make up 20-30% of all neuroendocrine cancers, yet their diversity and complexity have long puzzled researchers and clinicians. Now, thanks